Results

#ASH18: Celgene offers up a stellar complete response rate for JCAR017. Will anyone notice?

It’s getting harder and harder to make a splash with personalized CAR-Ts for leukemia and lymphoma, but Celgene is giving it a go today at ASH.

Their CAR-T team at Juno — now a subsidiary of Celgene’s — offered up a stellar round of objective responses rates for JCAR017 in their Phase I/II study for a small group of high-risk patients suffering from drug resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->